PUBLISHER: The Business Research Company | PRODUCT CODE: 1597002
PUBLISHER: The Business Research Company | PRODUCT CODE: 1597002
Bisoprolol is a beta-blocker used to treat high blood pressure, heart failure, and angina (chest pain). It functions by inhibiting the effects of adrenaline on the heart, which decreases heart rate and blood pressure, thereby easing the heart's workload.
Bisoprolol primarily comes in tablet and capsule forms. The tablet version is a solid oral medication intended for managing cardiovascular issues, providing a convenient and easily administered option for patients. It is generally prescribed in specific doses that facilitate a controlled release of the medication over time. Distribution channels include hospital pharmacies, retail pharmacies, and others, targeting conditions such as high blood pressure, coronary heart disease, and angina pectoris, among others.
The bisoprolol market research report is one of a series of new reports from the business research company that provides bisoprolol market statistics, including bisoprolol industry global market size, regional shares, competitors with an bisoprolol market share, detailed bisoprolol market segments, market trends and opportunities, and any further data you may need to thrive in the bisoprolol industry. This bisoprolol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bisoprolol market size has grown strongly in recent years. It will grow from $1.84 billion in 2023 to $2 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The increase during the historical period can be linked to the growing prevalence of cardiovascular diseases, an aging population, improved access to generic medications, heightened awareness of hypertension management, and rising healthcare spending.
The bisoprolol market size is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. During the forecast period, growth can be attributed to the expansion of cardiovascular specialty clinics, improved access to patient support programs, a rise in lifestyle-related diseases, an increase in clinical trials and research initiatives, and greater funding for cardiovascular health programs. Key trends expected in the forecast period include innovations in drug delivery systems, the development of therapies focused on patient needs, the integration of artificial intelligence in drug development, and progress in cardiovascular diagnostics.
The rising prevalence of hypertension is anticipated to drive the growth of the bisoprolol market in the future. Hypertension is characterized by consistently elevated blood pressure levels, influenced by factors such as sedentary lifestyles, obesity, and unhealthy diets. Bisoprolol is utilized to lower blood pressure by reducing the heart's workload and improving blood flow. For instance, in May 2024, the Singapore Heart Foundation reported that deaths due to hypertensive diseases accounted for 3.7% in 2022, up from 3.4% in 2021. Thus, the increasing prevalence of hypertension is expected to boost the bisoprolol market.
Key players in the bisoprolol market are focused on developing innovative formulations, such as generic combinations, to enhance accessibility, reduce costs, and expand their market presence. These generic combinations help manage high blood pressure, heart failure, and angina by lowering heart rate and improving circulation. For example, in November 2022, Zydus Lifesciences Limited received final approval from the U.S. Food and Drug Administration (FDA) for its extended-release bisoprolol fumarate and hydrochlorothiazide tablets in generic form. This formulation combines the beta-blocker bisoprolol, which decreases heart rate and blood pressure, with hydrochlorothiazide, a diuretic that reduces fluid retention. Together, they provide effective blood pressure management in a single extended-release tablet, promoting better patient adherence and long-term control of hypertension.
In April 2023, SK Capital Partners, LP, a U.S.-based private investment firm, acquired Apotex Inc. for an undisclosed amount. This acquisition aims to bolster Apotex's capabilities, accelerate growth, and foster innovation in the production of high-quality, affordable medicines globally. Apotex Inc. is a Canadian pharmaceutical company and a manufacturer of bisoprolol.
Major companies operating in the bisoprolol market are Merck & Co. Inc., Abbott Healthcare Pvt Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Cipla Limited, Hikma Pharmaceuticals, Lupin Limited, Dr. Reddy's Laboratories Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Ipca Laboratories Limited, Medreich Limited, Alembic Pharmaceuticals Limited, Accord Healthcare Limited, Zydus Lifesciences Limited, Zentiva Group, Taj Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Suanfarma, Rusan Healthcare Limited, VHB Lifesciences Limited, Synnat Pharmaceuticals, Vidakem Lifesciences Pvt Ltd, Pluviaendo Pharmaceuticals
North America was the largest region in the bisoprolol market in 2023. The regions covered in the bisoprolol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bisoprolol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The bisoprolol market consists of sales of generic medicine, extended-release tablets, and oral solutions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bisoprolol Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bisoprolol market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bisoprolol ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bisoprolol market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.